Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cytokinetics Inc

CYTK
Current price
41.29 USD +0.57 USD (+1.40%)
Last closed 41.22 USD
ISIN US23282W6057
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 806 852 096 USD
Yield for 12 month -34.84 %
1Y
3Y
5Y
10Y
15Y
CYTK
21.11.2021 - 28.11.2021

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

77.19 USD

P/E ratio

Dividend Yield

Current Year

+18 474 000 USD

Last Year

+7 530 000 USD

Current Quarter

+16 927 000 USD

Last Quarter

+463 000 USD

Current Year

+18 474 000 USD

Last Year

-322 593 000 USD

Current Quarter

-76 702 000 USD

Last Quarter

-84 149 000 USD

Key Figures CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -526 716 992 USD
Operating Margin TTM -821.41 %
Price to Earnings
Return On Assets TTM -30.11 %
PEG Ratio -0.42
Return On Equity TTM -572.15 %
Wall Street Target Price 77.19 USD
Revenue TTM 18 474 000 USD
Book Value -1.15 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 912.40 %
Dividend Yield
Gross Profit TTM -320 934 016 USD
Earnings per share -5.58 USD
Diluted Eps TTM -5.58 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CYTK

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:6
Payout Ratio TTM
Last Split Date 25.06.2013

Stock Valuation CYTK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 229.61
Price Sales TTM 260.20
Enterprise Value EBITDA -15.82
Price Book MRQ 60.31

Financials CYTK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CYTK

For 52 weeks

32.74 USD 68.44 USD
50 Day MA 42.56 USD
Shares Short Prior Month 14 220 519
200 Day MA 50.12 USD
Short Ratio 8.42
Shares Short 14 333 413
Short Percent 18.43 %